PAŠTĚKOVÁ, Lenka and David ŠMAJS. Low-dose versus standard-dose azithromycin for treatment of yaws. LANCET GLOBAL HEALTH. OXFORD: ELSEVIER SCI LTD, 2018, vol. 6, No 4, p. "E357"-"E358", 2 pp. ISSN 2214-109X. Available from: https://dx.doi.org/10.1016/S2214-109X(18)30067-6.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Low-dose versus standard-dose azithromycin for treatment of yaws
Authors PAŠTĚKOVÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution) and David ŠMAJS (203 Czech Republic, belonging to the institution).
Edition LANCET GLOBAL HEALTH, OXFORD, ELSEVIER SCI LTD, 2018, 2214-109X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30304 Public and environmental health
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 15.873
RIV identification code RIV/00216224:14110/18:00102804
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/S2214-109X(18)30067-6
UT WoS 000427125900004
Keywords in English azithromycin
Tags EL OK, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 23/4/2024 10:00.
Abstract
In their Article in The Lancet Global Health, Michael Marks and colleagues1 compare the efficacy of low-dose azithromycin (20 mg/kg) versus standard-dose azithromycin (30 mg/kg) for the treatment of yaws. The lower dose of azithromycin is commonly used for trachoma elimination and, since yaws and trachoma are co-endemic in several regions,2 mass treatment with low-dose azithromycin could also aid yaws eradication. If a low-dose azithromycin treatment is as effective against yaws as standard-dose azithromycin, yaws eradication programmes can expect a considerable cost saving.
PrintDisplayed: 29/7/2024 10:32